| dc.contributor.advisor | Castano Molina, Carlos Eduardo | |
| dc.contributor.author | Giraldo Gonzalez, German Camilo | |
| dc.date.accessioned | 2024-06-05T20:44:58Z | |
| dc.date.available | 2024-06-05T20:44:58Z | |
| dc.date.issued | 2024-06-05 | |
| dc.identifier.uri | https://repositorio.ucaldas.edu.co/handle/ucaldas/19927 | |
| dc.description | Ilustraciones | spa |
| dc.description.abstract | No existen datos respecto al perfil genético de riesgo cardiovascular en pacientes con diabetes mellitus tipo 2 (DMT2) y enfermedad cardiovascular, en población colombiana. Estos pacientes representan una alta recurrencia de enfermedad cardiovascular y suelen requerir más intervenciones. Métodos y resultados: se realizó un estudio de epidemiología genética transversal en el que se analizaron 11 alelos de riesgo para eventos cardiovasculares y se buscó asociación con la complejidad de la enfermedad coronaria y los factores de riesgo clínicos y metabólicos. Se documentó una alta prevalencia de homocigosis de los alelos, teniendo el 99% de los pacientes al menos. Cada alelo por
aparte no logró ser diferenciador y en los alelos de riesgo más frecuentes agrupados,tampoco lograron significancia estadística. Sin embargo; por eliminación acorde a asociaciones de GWAS para enfermedad coronaria, se encontraron 5 alelos con un OR de 5,2 p 0.007 para enfermedad coronaria más compleja. Al comparar por edad, sexo, factores
de riesgo tradicionales, historia familiar, factores metabólicos, no se encontraron diferencias estadísticamente significativas. Conclusión: un grupo de 5 alelos presente en pacientes con DMT2 y enfermedad cardiovascular es potencialmente evaluable en estudios prospectivos
o de casos y controles para establecer su capacidad de predicción del riesgo cardiovascular. | spa |
| dc.description.abstract | There are no data regarding the genetic profile of cardiovascular risk in patients with diabetes mellitus type 2 (T2DM) and cardiovascular disease in the Colombian population. These patients represent a high recurrence of cardiovascular disease and usually require
more interventions. Methods and results: a cross-sectional genetic epidemiology study was carried out in which 11 risk alleles for cardiovascular events were analyzed and an association was sought with the complexity of coronary heart disease and clinical and
metabolic risk factors. A high prevalence of homozygosity of the alleles was documented, with 99% of patients having at least 3. Each allele separately failed to be differentiating. The most frequent risk alleles grouped together also did not achieve statistical significance.
However, by elimination according to GWAS associations for coronary heart disease, 5 alleles were found with an OR of 5.2 p 0.007 for more complex coronary heart disease. When comparing by age, sex, traditional risk factors, family history, and metabolic factors,
no statistically significant differences were found. Conclusion: a group of 5 alleles present in patients with T2DM and cardiovascular disease is potentially evaluated in prospective orcase-control studies to establish its ability to predict cardiovascular risk | eng |
| dc.description.tableofcontents | INTRODUCCIÓN /
1. PLANTEAMIENTO DEL PROBLEMA Y ANTECEDENTES /
1.1 El riesgo cardiovascular /
1.2 Factores de riesgo /
1.3 Pregunta de investigación /
2. JUSTIFICACIÓN /
3. REFERENTE TEÓRICO /
3.1 Diabetes tipo 2 /
3.1.1 Fisiopatología de la diabetes tipo 2 /
3.1.2 Diagnóstico /
3.1.3 Cuadro clínico /
3.1.4 Tratamiento /
3.1.5 Complicaciones /
3.2 Enfermedad cardiovascular /
3.2.1 Evaluación del riesgo cardiovascular del paciente con diabetes tipo 2 /
3.2.1Tratamiento /
3.2.2 Objetivos terapéuticos /
3.3 Genética /
4. OBJETIVOS /
4.1 Objetivo general /
4.2 Objetivos específicos /
5. METODOLOGÍA /
5.1 Tipo de estudio /
5.2 Población /
5.2.1 Muestra /
5.2.2 Criterios de inclusión /
5.2.3 Criterios de exclusión /
5.3 Variables /
5.4 Plan de análisis de la información /
6. CONSIDERACIONES ÉTICAS /
7. RESULTADOS /
8. DISCUSIÓN /
9. CONCLUSIONES Y RECOMENDACIONES /
9.1 Conclusiones /
9.2 Recomendaciones /
REFERENCIAS BIBLIOGRÁFICAS / | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.language.iso | eng | spa |
| dc.language.iso | spa | spa |
| dc.title | Factores clínicos y genéticos asociados a eventos cardiovasculares en pacientes con diabetes tipo 2 | spa |
| dc.type | Trabajo de grado - Doctorado | spa |
| dc.contributor.researchgroup | Promoción de la Salud y Prevención de la Enfermedad (Categoría A) | spa |
| dc.description.degreelevel | Doctorado | spa |
| dc.identifier.instname | Universidad de Caldas | spa |
| dc.identifier.reponame | Repositorio Institucional Universidad de Caldas | spa |
| dc.identifier.repourl | https://repositorio.ucaldas.edu.co/ | spa |
| dc.publisher.faculty | Facultad de Ciencias para la Salud | spa |
| dc.publisher.place | Manizales | spa |
| dc.relation.references | Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics - 2023 Update: A Report from the American Heart Association. Vol. 147, Circulation. Lippincott Williams and Wilkins; 2023. p. E93– 621. | spa |
| dc.relation.references | Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Vol. 17, Cardiovascular Diabetology. BioMed Central Ltd; 2018. | spa |
| dc.relation.references | Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia [Internet]. 2022; 65:3–13. Available from: https://doi.org/10.1007/s00125-021-05585-2 | spa |
| dc.relation.references | Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct 1;9(10):653–62. | spa |
| dc.relation.references | Senior JR. Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges. Vol. 37, Drug Safety. Springer International Publishing; 2014. p. 9–17. | spa |
| dc.relation.references | Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, et al. Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. Vol. 12, Frontiers in Pharmacology. Frontiers Media S.A.; 2022. | spa |
| dc.relation.references | Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. Vol. 79, Journal of the American College of Cardiology. Elsevier Inc.; 2022. p. 1849–57. | spa |
| dc.relation.references | Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Vol. 34, Canadian Journal of Cardiology. Elsevier Inc.; 2018. p. 575–84. | spa |
| dc.relation.references | Witka BZ, Oktaviani DJ, Marcellino M, Barliana MI, Abdulah R. Type 2 diabetesassociated genetic polymorphisms as potential disease predictors. Vol. 12, Diabetes, Metabolic Syndrome and Obesity. Dove Medical Press Ltd; 2019. p. 2689–706. | spa |
| dc.relation.references | Seyerle AA, Avery CL. Understanding Genetic Epidemiology: The Potential Benefits and Challenges of Genetics for Improving Human Health. Vol. 74, N C Med J. 2013. | spa |
| dc.relation.references | Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Vol. 14, Future Cardiology. Future Medicine Ltd.; 2018. p. 491–509. | spa |
| dc.relation.references | Muñoz OM, Rodríguez NI, Ruiz Á, Rondón M. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Revista Colombiana de Cardiologia. 2014;21(4):202–12. | spa |
| dc.relation.references | Costantino S, Ambrosini S, Paneni F. The epigenetic landscape in the cardiovascular complications of diabetes. Vol. 42, Journal of Endocrinological Investigation. Springer International Publishing; 2019. p. 505–11. | spa |
| dc.relation.references | Deedwania P. Emerging strategies for diabetes and cardiovascular disorders: Introduction and foreword. Prog Cardiovasc Dis. 2019 Jul 1;62(4):295–7. | spa |
| dc.relation.references | Szuszkiewicz-Garcia MM, Davidson JA. Cardiovascular disease in diabetes mellitus: Risk factors and medical therapy. Vol. 43, Endocrinology and Metabolism Clinics of North America. 2014. p. 25–40. | spa |
| dc.relation.references | Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes— 2023. Diabetes Care. 2023 Jan 1;46:S158–90. | spa |
| dc.relation.references | Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, et al. Recurrence of cardiovascular events in patients with type 2 diabetes: Epidemiology and risk factors. Diabetes Care. 2008 Nov;31(11):2154–9. | spa |
| dc.relation.references | Govender RD, Al-Shamsi S, Soteriades ES, Regmi D. Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: A retrospective study. BMC Cardiovasc Disord. 2019 Nov 11;19(1). | spa |
| dc.relation.references | Fallin MD, Duggal P, Beaty TH. Genetic epidemiology and public health: The evolution from theory to technology. Vol. 183, American Journal of Epidemiology. Oxford University Press; 2016. p. 387–93. | spa |
| dc.relation.references | Goyal S, Sanghera DK. Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians. Curr Diabetes Rev. 2021 Jan 19;17(9). | spa |
| dc.relation.references | Goodarzi MO, Rotter JI. Genetics Insights in the Relationship between Type 2 Diabetes and Coronary Heart Disease. Vol. 126, Circulation Research. Lippincott Williams and Wilkins; 2020. p. 1526–48. | spa |
| dc.relation.references | Knowles JW, Ashley EA. Cardiovascular disease: The rise of the genetic risk score. PLoS Med. 2018 Mar 1;15(3). | spa |
| dc.relation.references | Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. J Am Coll Cardiol. 2018 Oct 16;72(16):1883– 93. | spa |
| dc.relation.references | Lu T, Forgetta V, Yu OHY, Mokry L, Gregory M, Thanassoulis G, et al. Polygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes. Cardiovasc Diabetol. 2020 Jan 30;19(1). | spa |
| dc.relation.references | Abdullah Said M, Verweij N, Van Der Harst P. Associations of combined genetic and lifestyle risks with incident cardiovascular disease and diabetes in the UK biobank study. JAMA Cardiol. 2018 Aug 1;3(8):693–702. | spa |
| dc.relation.references | Cox AJ, Hsu FC, Ng MCY, Langefeld CD, Freedman BI, Carr JJ, et al. Genetic risk score associations with cardiovascular disease and mortality in the diabetes heart study. Diabetes Care. 2014;37(4):1157–64. | spa |
| dc.relation.references | Gloyn AL, Drucker DJ. Precision medicine in the management of type 2 diabetes. Vol. 6, The Lancet Diabetes and Endocrinology. Lancet Publishing Group; 2018. p. 891–900. | spa |
| dc.relation.references | Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Vol. 50, Endocrinology and Metabolism Clinics of North America. W.B. Saunders; 2021. p. 337–55. | spa |
| dc.relation.references | Yun JS, Ko SH. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Vol. 123, Metabolism: Clinical and Experimental. W.B. Saunders; 2021. | spa |
| dc.relation.references | Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Vol. 21, International Journal of Molecular Sciences. MDPI AG; 2020. p. 1–34. | spa |
| dc.relation.references | Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Vol. 21, Cardiovascular Diabetology. BioMed Central Ltd; 2022. | spa |
| dc.relation.references | Nathan D. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;30:977–86. | spa |
| dc.relation.references | Turner Robert. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). LANCET. 1998;852:837–53. | spa |
| dc.relation.references | Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. The Lancet. 2010;376(9739):419–30. | spa |
| dc.relation.references | Steiner S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Vol. 13, Zeitschrift fur Gefassmedizin. Krause und Pachernegg GmbH; 2016. p. 17–8. | spa |
| dc.relation.references | Marso SP DGBFKKPMJNMNS. Liraglutide and cardiovascular outcomes in type 2 diabetes. Vol. 54, N Engl J Med. BMJ Publishing Group; 2016. p. 101. | spa |
| dc.relation.references | Strawbridge RJ, van Zuydam NR. Shared Genetic Contribution of Type 2 Diabetes and Cardiovascular Disease: Implications for Prognosis and Treatment. Vol. 18, Current Diabetes Reports. Current Medicine Group LLC 1; 2018. | spa |
| dc.relation.references | Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043–140. | spa |
| dc.relation.references | Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019 Jan 3;380(1):11–22. | spa |
| dc.relation.references | Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017 Sep 21;377(12):1119–31. | spa |
| dc.relation.references | Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine. 2018 Nov 29;379(22):2097–107. | spa |
| dc.relation.references | Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017 May 4;376(18):1713–22. | spa |
| dc.relation.references | Ntalla I, Kanoni S, Zeng L, Giannakopoulou O, Danesh J, Watkins H, et al. Genetic Risk Score for Coronary Disease Identifies Predispositions to Cardiovascular and Noncardiovascular Diseases. J Am Coll Cardiol. 2019 Jun 18;73(23):2932–42. | spa |
| dc.relation.references | Nelson CP, Goel A, Butterworth AS, Kanoni S, Webb TR, Marouli E, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nat Genet. 2017 Sep 1;49(9):1385–91. | spa |
| dc.relation.references | Smith JA, Ware EB, Middha P, Beacher L, Kardia SLR. Current Applications of Genetic Risk Scores to Cardiovascular Outcomes and Subclinical Phenotypes. Curr Epidemiol Rep. 2015 Sep;2(3):180–90. | spa |
| dc.relation.references | Pereira A, Mendonça MI, Borges S, Freitas S, Henriques E, Rodrigues M, et al. Genetic risk analysis of coronary artery disease in a population-based study in Portugal, using a genetic risk score of 31 variants. Arq Bras Cardiol. 2018 Jul 1;111(1):50–61. | spa |
| dc.relation.references | van Setten J, Isgum I, Smolonska J, Ripke S, de Jong PA, Oudkerk M, et al. Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. Atherosclerosis. 2013 Jun;228(2):400–5. | spa |
| dc.relation.references | Verbeek R, Oldoni F, Surendran RP, Zwinderman AH, Khaw KT, Stroes ESG, et al. A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. J Clin Lipidol. 2019 May 1;13(3):492–501. | spa |
| dc.relation.references | Thanassoulis G, Peloso GM, Pencina MJ, Hoffmann U, Fox CS, Cupples LA, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium the framingham heart study. Circ Cardiovasc Genet. Feb;5(1):113–21. | spa |
| dc.relation.references | De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links. Vol. 9, Frontiers in Endocrinology. Frontiers Media S.A.; 2018. | spa |
| dc.relation.references | Qi L, Parast L, Cai T, Powers C, Gervino E V., Hauser TH, et al. Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies. J Am Coll Cardiol. 2011 Dec 13;58(25):2675–82. | spa |
| dc.relation.references | Shah HS, Morieri ML, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, et al. Modulation of GLP-1 levels by a genetic variant that regulates the cardiovascular effects of intensive glycemic control in ACCORD. Diabetes Care. 2018 Feb 1;41(2):348–55. | spa |
| dc.relation.references | Langenberg C, Lotta LA. Genomic insights into the causes of type 2 diabetes. Vol. 391, The Lancet. Lancet Publishing Group; 2018. p. 2463–74. | spa |
| dc.relation.references | Wheeler E, Leong A, Liu CT, Hivert MF, Strawbridge RJ, Podmore C, et al. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med. 2017 Sep 1;14(9). | spa |
| dc.relation.references | Emdin CA, Khera A V., Chaffin M, Klarin D, Natarajan P, Aragam K, et al. Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nat Commun. 2018 Dec 1;9(1). | spa |
| dc.relation.references | Bressler J, Folsom AR, Couper DJ, Volcik KA, Boerwinkle E. Genetic variants identified in a European genome-wide association study that were found to predict incident coronary heart disease in the atherosclerosis risk in communities study. Am J Epidemiol. 2010 Jan;171(1):14–23. | spa |
| dc.relation.references | Congrains A, Kamide K, Oguro R, Yasuda O, Miyata K, Yamamoto E, et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis. 2012 Feb;220(2):449–55. | spa |
| dc.relation.references | Xu B, Fang Z, He S, Wang J, Yang X. ANRIL polymorphism rs4977574 is associated with increased risk of coronary artery disease in Asian populations: A metaanalysis of 12,005 subjects. Vol. 97, Medicine (United States). Lippincott Williams and Wilkins; 2018. | spa |
| dc.relation.references | Zheng JS, Arnett DK, Parnell LD, Smith CE, Li D, Borecki IB, et al. Modulation by dietary fat and carbohydrate of IRS1 association with type 2 diabetes traits in two populations of different ancestries. Diabetes Care. 2013 Sep;36(9):2621–7. | spa |
| dc.relation.references | Paquette M, Dufour R, Baass A. PHACTR1 genotype predicts coronary artery disease in patients with familial hypercholesterolemia. J Clin Lipidol. 2018 Jul 1;12(4):966–71. | spa |
| dc.relation.references | Castillo-Avila RG, González-Castro TB, Tovilla-Zárate CA, Martínez-Magaña JJ, López-Narváez ML, Juárez-Rojop IE, et al. Association between Genetic Variants of CELSR2-PSRC1-SORT1 and Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Vol. 10, Journal of Cardiovascular Development and Disease. | spa |
| dc.relation.references | Kleber ME, Grammer TB, Renner W, März W. Effect of the rs2259816 polymorphism in the HNF1A gene on circulating levels of c-reactive protein and coronary artery disease (the ludwigshafen risk and cardiovascular health study). BMC Med Genet. 2010 Nov 9;11(1). | spa |
| dc.relation.references | Estrada K, Aukrust I, Bjørkhaug L, Burtt NP, Mercader JM, García-Ortiz H, et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a latino population the SIGMA Type 2 Diabetes Consortium. JAMA. 2014 Jun 11;311(22):2305–14. | spa |
| dc.relation.references | Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes. 2010 Feb;59(2):479–85. | spa |
| dc.relation.references | Huang Y, Ye HD, Gao X, Nie S, Hong QX, Ji HH, et al. Significant interaction of APOE rs4420638 polymorphism with HDL-C and APOA-I levels in coronary heart disease in Han Chinese men. Genetics and Molecular Research. 2015 Oct 28;14(4):13414–24. | spa |
| dc.relation.references | Liu C, Li Y, Guan T, Lai Y, Shen Y, Zeyaweiding A, et al. ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus. Cardiovasc Diabetol. 2018 Sep 18;17(1). | spa |
| dc.relation.references | Huang Y, Jin H, Yang G. Associations Between Common Polymorphisms of CDKN2B-AS and Susceptibility to ASCVD. Angiology. 2020 Nov 1;71(10):934–41. | spa |
| dc.relation.references | Shukla H, Mason JL, Sabyah A. Identifying genetic markers associated with susceptibility to cardiovascular diseases. Vol. 5, Future Science OA. Future Medicine Ltd.; 2019. | spa |
| dc.relation.references | Naito R, Miyauchi K. Coronary Artery Disease and Type 2 Diabetes Mellitus Current Treatment Strategies and Future Perspective. 2017. | spa |
| dc.relation.references | Thanassoulis G, Peloso GM, Pencina MJ, Hoffmann U, Fox CS, Cupples LA, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium the framingham heart study. Circ Cardiovasc Genet. Feb;5(1):113–21. | spa |
| dc.relation.references | Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Vol. 183, Translational Research. Mosby Inc.; 2017. p. 57–70 | spa |
| dc.relation.references | Talmud PJ, Cooper JA, Palmen J, Lovering R, Drenos F, Hingorani AD, et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem. 2008 Mar 1;54(3):467–74. | spa |
| dc.relation.references | Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events A bs t r ac t [Internet]. Vol. 358, N Engl J Med. 2008. Available from: www.nejm.org | spa |
| dc.relation.references | Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010 Feb 17;303(7):631–7. | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.subject.proposal | Type 2 diabetes mellitus cardiovascular disease genetics coronary heart disease | eng |
| dc.subject.proposal | Enfermedad cardiovascular | spa |
| dc.subject.proposal | Genética | spa |
| dc.subject.proposal | Enfermedad coronaria | spa |
| dc.subject.proposal | Diabetes tipo 2 | spa |
| dc.subject.proposal | Type 2 diabetes | eng |
| dc.subject.proposal | Mellitus cardiovascular | eng |
| dc.subject.proposal | Disease genetics | eng |
| dc.subject.proposal | Coronary heart disease | eng |
| dc.subject.unesco | Ciencias médicas | |
| dc.type.coar | http://purl.org/coar/resource_type/c_db06 | spa |
| dc.type.content | Text | spa |
| dc.type.driver | info:eu-repo/semantics/doctoralThesis | spa |
| dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
| oaire.version | http://purl.org/coar/version/c_ab4af688f83e57aa | spa |
| oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.description.degreename | Doctor(a) en Ciencias de la Salud | spa |
| dc.publisher.program | Doctorado en Ciencias de la Salud | spa |
| dc.description.researchgroup | clinica | spa |
| dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | spa |
